Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial

Autor: Juan P. Frias, Donald C. Simonson, Marcia A. Testa, Guillermo Gonzalez‐Galvez, Anne L. Peters, Jill Maaske, Nalina Dronamraju, Eva Johnsson, Ricardo Garcia-Sanchez
Rok vydání: 2020
Předmět:
Blood Glucose
Endocrinology
Diabetes and Metabolism
Adamantane
Type 2 diabetes
030204 cardiovascular system & hematology
Saxagliptin
law.invention
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Glucosides
Randomized controlled trial
law
saxagliptin
Dapagliflozin
glimepiride
intensification
Dipeptides
Middle Aged
Metformin
glycaemic control
Treatment Outcome
Original Article
Drug Therapy
Combination
medicine.drug
medicine.medical_specialty
Urology
GLIM
030209 endocrinology & metabolism
03 medical and health sciences
Double-Blind Method
Diabetes mellitus
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Benzhydryl Compounds
Aged
Glycated Hemoglobin
business.industry
Original Articles
dapagliflozin
medicine.disease
Hypoglycemia
Glimepiride
Sulfonylurea Compounds
Diabetes Mellitus
Type 2
chemistry
business
Zdroj: Diabetes, Obesity & Metabolism
ISSN: 1463-1326
1462-8902
DOI: 10.1111/dom.13997
Popis: Aims To evaluate the efficacy and safety of dapagliflozin (DAPA) + saxagliptin (SAXA) compared with glimepiride (GLIM) in patients with type 2 diabetes who were inadequately controlled [glycated haemoglobin (HbA1c) 7.5–10.5% (58–91 mmol/mol)] on metformin monotherapy. Materials and methods This 52‐week, multicentre, double‐blind, active‐controlled study (NCT02419612) randomized (1:1) patients on metformin to add‐on DAPA 10 mg + SAXA 5 mg (n = 227) or GLIM 1–6 mg (titrated; n = 217). The primary efficacy endpoint was change in HbA1c from baseline to week 52. Results Baseline mean ± standard deviation of age, duration of diabetes and HbA1c were 56.1 ± 9.7 years, 7.8 ± 6.4 years and 8.5% ± 0.8% (69 ± 9.0 mmol/mol), respectively. Adjusted mean change from baseline in HbA1c was −1.35% (−14.8 mmol/mol) with DAPA + SAXA versus −0.98% (−10.7 mmol/mol) with GLIM (P
Databáze: OpenAIRE
Externí odkaz: